- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval ; volume:83 ; number:16 ; day:31 ; month:10 ; year:2023 ; pages:1543 ; date:11.2023
Drugs ; 83, Heft 16 (31.10.2023), 1543, 11.2023
- Klassifikation
-
Recht
- Urheber
-
Syed, Yahiya Y.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-023-01965-7
- URN
-
urn:nbn:de:101:1-2024012212102665531715
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Syed, Yahiya Y.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lotilaner Ophthalmic Solution 0.25%: First Approval
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction: Eplontersen: First Approval
Correction: Zilucoplan: First Approval
Correction: Vorasidenib: First Approval
Correction: Elacestrant: First Approval
Approval and Certification of Ophthalmic AI Devices in the European Union
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Lenacapavir: First Approval
Correction to: Nedosiran: First Approval
Lotilaner Ophthalmic Solution 0.25%: First Approval
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction: Eplontersen: First Approval
Correction: Zilucoplan: First Approval
Correction: Vorasidenib: First Approval
Correction: Elacestrant: First Approval
Approval and Certification of Ophthalmic AI Devices in the European Union
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Lenacapavir: First Approval
Correction to: Nedosiran: First Approval
Lotilaner Ophthalmic Solution 0.25%: First Approval
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction: Eplontersen: First Approval
Correction: Zilucoplan: First Approval
Correction: Vorasidenib: First Approval
Correction: Elacestrant: First Approval
Approval and Certification of Ophthalmic AI Devices in the European Union
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Lenacapavir: First Approval